ALLMedicine™ Adrenocortical Carcinoma Center
Research & Reviews 745 results
https://doi.org/10.1186/s12890-022-02036-5 10.2991/jegh.k.191008.001 10.1515/med-2021-0321 10.1016/j.cllc.2021.07.011 10.3322/caac.21654 10.3390/cancers12092522 10.1016/j.biopha.2020.111111 10.1002/2211-5463.12819 10.3389/fonc.2020.01546 10.1016/j.surg.2019.03.041 10.1007/s40618-017-0783-y 10.1371/journal.pgen.0030161 10.1002/cam4.4285 10.7717/peerj.11968 10.1186/s12916-021-02027-z 10.1186/1471-2105-12-77 10.1186/s12935-021-02278-z 10.1186/s12916-021-02134-x 10.1093/nar/gky1094 10.1093/nar/gkw983 10.1186/s12967-021-02915-1 10.1002/2211-5463.13256 10.1186/s12920-021-01007-9 10.1093/nar/gkab1113 10.1093/bioinformatics/btr064 10.1089/omi.2011.0118 10.7717/peerj.12253 10.2147/IJGM.S333697 10.1038/nature08822 10.1186/s12885-021-08796-3 10.1016/j.ebiom.2020.103074 10.1016/j.immuni.2018.03.023 10.1158/0008-5472.CAN-17-0307 10.1038/ncomms3612 10.1093/bioinformatics/btz210 10.1136/ebmental-2019-300117 10.1038/nature14664 10.3389/fimmu.2020.00369 10.1093/jnci/djy085 10.5858/2002-126-0042-IAOPAP 10.1002/hep.20337 10.1128/MCB.23.4.1269-1277.2003 10.1530/ERC-13-0445 10.1093/annonc/mdy495 10.3390/cells9040801 10.1016/j.celrep.2018.03.124 10.1007/s11684-016-0478-3 10.1038/srep13781
BMC Pulmonary Medicine; Li GS, Chen G et. al.
Jun 25th, 2022 - Cyclin-dependent kinase inhibitor 2C (CDKN2C) was identified to participate in the occurrence and development of multiple cancers; however, its roles in small cell lung carcinoma (SCLC) remain unclear. Differential expression analysis of CDKN2C be...
https://doi.org/10.1007/s40618-022-01836-0 10.1016/j.endinu.2020.03.002 10.1530/EJE-16-0467 10.1210/jcem.85.2.6372 10.1016/j.surg.2004.06.060 10.1530/EJE-09-0234 10.1089/LAP.2020.0505 10.1016/S1473-3099(13)70324-4 10.1210/jc.2008-0125 10.1210/jc.2015-4061 10.1210/jc.2014-1498 10.1007/s12020-019-01888-y 10.2214/ajr.183.1.1830215 10.1097/01.SLA.0000133083.54934.AE 10.1530/ERC-21-0230 10.1007/s12020-021-02843-6 10.1097/00000478-198403000-00001 10.1177/106689690401200304 10.1056/NEJMCP2031112 10.1016/J.SURG.2012.08.011 10.1016/J.BEEM.2020.101427 10.21037/GS-20-559 10.1007/S40618-020-01198-5 10.3390/IJMS23020637 10.1530/EJE-18-0450 10.1007/S00464-015-4643-6 10.1038/s41598-022-06655-0 10.1530/EJE-15-0036 10.1186/S12893-021-01080-Y 10.1007/S00464-021-08380-7 10.1186/s12957-019-1649-x 10.23736/S0393-2249.19.03440-4 10.1016/J.EJSO.2020.01.031 10.1111/CEN.13883 10.1007/S40618-021-01615-3
Journal of Endocrinological Investigation; Mínguez Ojeda C, Gómez Dos Santos V et. al.
Jun 25th, 2022 - To evaluate the relevance of tumour size in adrenal tumours in the estimation of malignancy risk and in the outcomes of adrenalectomy. We evaluate the histological results and surgical outcomes (intraoperative and postsurgical complications) in a ...
https://clinicaltrials.gov/ct2/show/NCT04358107
Jun 24th, 2022 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...
https://clinicaltrials.gov/ct2/show/NCT05237934
Jun 24th, 2022 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...
https://clinicaltrials.gov/ct2/show/NCT04447014
Jun 24th, 2022 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...
Guidelines 3 results
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.
Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...
https://doi.org/10.1530/EJE-16-0467
European Journal of Endocrinology; Fassnacht M, Arlt W et. al.
Jul 9th, 2016 - : By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent con...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.
Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...
Clinicaltrials.gov 45 results
https://clinicaltrials.gov/ct2/show/NCT04447014
Jun 24th, 2022 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...
https://clinicaltrials.gov/ct2/show/NCT05237934
Jun 24th, 2022 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...
https://clinicaltrials.gov/ct2/show/NCT04358107
Jun 24th, 2022 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...
https://clinicaltrials.gov/ct2/show/NCT03583710
Jun 8th, 2022 - PRIMARY OBJECTIVE: I. To compare the effect of adjuvant mitotane treatment alone (arm A) with that of adjuvant mitotane combined with four 21-day cycles of etoposide/cisplatin (arm B) on recurrence-free survival (RFS) in patients with high-risk ad...
https://clinicaltrials.gov/ct2/show/NCT00568139
May 19th, 2022 - Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many side effects are not well documented. Therefore, we are aiming at collecting data about side effects in patients treated with mitotane
News 25 results
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer
Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...
https://www.medscape.com/viewarticle/959868
Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...
https://www.onclive.com/view/advanced-hcc-whats-next
Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: I would like to end our very valuable discussion here by asking each one of you about—all right, great, out of nothing we moved in the speed of light. I’m not sure even if there is any other disease that w...
https://www.medscape.com/viewarticle/934790
Jul 29th, 2020 - A strategy that includes a urine steroid test along with imaging characteristics and tumor size criteria can significantly improve the challenging diagnosis of adrenocortical cancer, helping to avoid unnecessary, and often unsuccessful, further im...
https://reference.staging.medscape.com/viewarticle/904250
Nov 5th, 2018 - Clinical practice guidelines for the management of adrenocortical carcinoma in adults were released in October 2018 by the European Society of Endocrinology.[1] Diagnosis Perform a detailed hormonal workup of all patients with suspected adrenocort...
